# Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

> **NCT05833919** · PHASE2 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 122 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05833919
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-30
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833919, "Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05833919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*